Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Axovant to pull plug on Alzheimer’s drug

Drug developer Axovant Sciences Ltd. said it would stop testing the company’s lead drug in Alzheimer’s after it failed to meet the main goals of a late-stage trial.

Read More »

Genocea Shifts R&D Focus in Restructuring

Genocea Biosciences is pivoting a development strategy to focus on development of neoantigen cancer treatments and scrapping its Phase III-ready herpes drug.

Read More »

Vertex Ends Phase II CF Trial

Vertex Pharmaceuticals reportedly terminated a long-acting trial combining a recently acquired therapy with the company’s cystic fibrosis drug Kalydeco.

Read More »

Clinical Study Shows That Retinal Imaging May Detect Signs of Alzheimer’s Disease

A study led by researchers at Cedars-Sinai and NeuroVision Imaging LLC provides the scientific basis for using noninvasive eye imaging to detect the pathological hallmarks of Alzheimer’s. The experimental technology, developed by Cedars-Sinai and NeuroVision, scans the retina using techniques that can identify beta-amyloid protein deposits that mirror those in the brain.

Read More »

Celgene Revamps Pact With Sutro Biopharma

Sutro Biopharma and Celgene modified their 2014 immuno-oncology collaboration revolving around four programs that are in preclinical development.

Read More »

Roche unloads some rights to drug hopeful after asthma trial disappointment

Roche is offloading some rights to what was once one of its top drug prospects, lebrikizumab, for payments that could total more than $1 billion after the medicine produced only lackluster results in an asthma study during 2016.

Read More »

Lilly’s acute migraine drug succeeds in Phase III

Drugmaker Eli Lilly and Co. said its acute migraine drug lasmiditan succeeded in a key late-stage study, setting the stage for U.S. regulatory approval.

Read More »

Sleep disruption increases Alzheimer’s-related protein levels

Disrupting deep sleep boosts the amount of an Alzheimer’s disease-related protein called amyloid-beta in the fluid bathing the brain and spinal cord, new research suggests.

Read More »

Alder’s migraine drug data disappoints

Alder BioPharmaceuticals’ late-stage study data on its experimental treatment to prevent episodic migraine fell short of investors’ expectation.

Read More »

Sanofi Commits $673 Million in Biologics

Sanofi plans to invest $673 million annually over the next two to three years in biologics production.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!


Ad Right Bottom